NATHANIEL LARTEY LARTEY

Dr. NATHANIEL LARTEY LARTEY

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
FAFrederick Ayertey
Frederick Ayertey
EOEbenezer Ofori-Attah
Ebenezer Ofori-Attah
SAStephen Antwi
Stephen Antwi
MAMichael Amoa-Bosompem
Michael Amoa-Bosompem
GDGeorgina Djameh
Georgina Djameh
LOLaud Kenneth Okine
Laud Kenneth Okine
Most developing countries resort to medicinal plants for treating diseases, but few of these have scientific backing for their use. The aim of the study was to validate traditional use of Morinda lucida leaves in treating inflammation and determine the mechanism of action. Effect of hydroethanolic leaf extract of M. lucida (HEML) on localized inflammation was evaluated using rat paw edema presented by sub-planter injections of λ-carrageenan, histamine or serotonin in separate experiments. Systemic inflammation was evaluated by lipopolysaccharide (LPS)-induced hyperthermia. Antioxidant activity of HEML was also evaluated using the free-radical scavenging assay. No mortalities were recorded in acute toxicity assay after administering 5000 mg/kg HEML to rats. It showed very good activity against localized and systemic inflammation in inverse dose-dependent manner and caused reduction in nitric oxide and prostaglandin E−2 levels by affecting expression of inducible nitric oxide synthase, but not cyclooxygenases-2 in LPS-activated RAW 264.7 murine macrophages. HEML reduced pro-inflammatory cytokines interleukin (IL)-1β and tumor necrotic factor, but elevated levels of anti-inflammatory cytokine IL-10 in vitro. HEML contains saponins, reducing sugars, polyphenols and flavonoids and showed antioxidant activity with EC50 = 0.6415 ± 0.0027 mg/ml. In conclusion, this study provides evidence that HEML possesses anti-inflammatory activity, possibly through modulation of production of early/late phase inflammation mediators.

23 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CCCI CHEN
CI CHEN
MEMartijn Alexander van der Ent
Martijn Alexander van der Ent
NLNATHANIEL LARTEY LARTEY
NATHANIEL LARTEY LARTEY
PKPhilip D. King
Philip D. King
Ephrin receptors constitute a large family of receptor tyrosine kinases in mammals that through interaction with cell surface-anchored ephrin ligands regulate multiple different cellular responses in numerous cell types and tissues. In the cardiovascular system, studies performed in vitro and in vivo have pointed to a critical role for Ephrin receptor B4 (EPHB4) as a regulator of blood and lymphatic vascular development and function. However, in this role, EPHB4 appears to act not as a classical growth factor receptor but instead functions to dampen the activation of the Ras-mitogen activated protein signaling (MAPK) pathway induced by other growth factor receptors in endothelial cells (EC). To inhibit the Ras-MAPK pathway, EPHB4 interacts functionally with Ras p21 protein activator 1 (RASA1) also known as p120 Ras GTPase-activating protein. Here, we review the evidence for an inhibitory role for an EPHB4–RASA1 interface in EC. We further discuss the mechanisms by which loss of EPHB4–RASA1 signaling in EC leads to blood and lymphatic vascular abnormalities in mice and the implications of these findings for an understanding of the pathogenesis of vascular anomalies in humans caused by mutations in EPHB4 and RASA1 genes. Last, we provide insights into possible means of drug therapy for EPHB4- and RASA1-related vascular anomalies.

28 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
NLNATHANIEL LARTEY LARTEY
NATHANIEL LARTEY LARTEY
HVHilda Vargas-Robles
Hilda Vargas-Robles
IFIdaira María Guerrero Fonseca
Idaira María Guerrero Fonseca
AGAlexander García-Ponce
Alexander García-Ponce
CSCitlaltepetl Salinas-Lara
Citlaltepetl Salinas-Lara
MSMichael Schnoor
Michael Schnoor
Sepsis is a systemic infection that can lead to multi-organ failure. It is characterised by an uncontrolled immune response with massive neutrophil influx into peripheral organs. Neutrophil extravasation into tissues depends on actin remodeling and actin-binding proteins such as cortactin, which is expressed ubiquitously, except for neutrophils. Endothelial cortactin is necessary for proper regulation of neutrophil transendothelial migration and recruitment to sites of infection. We therefore hypothesised that cortactin plays a crucial role in sepsis development by regulating neutrophil trafficking. Using a murine model of sepsis induced by cecal ligation and puncture (CLP), we showed that cortactin-deficient (KO) mice survive better due to reduced lung injury. Histopathological analysis of lungs from septic KO mice revealed absence of oedema, reduced vascular congestion and mucus deposition, and better-preserved alveoli compared to septic wild-type (WT) mice. Additionally, sepsis-induced cytokine storm, excessive neutrophil infiltration into the lung and oxidative stress were significantly reduced in KO mice. Neutrophil depletion 12 h after sepsis improved survival in WT mice by averting lung injury, similar to both neutrophil-depleted and non-depleted KO mice. Our findings highlight a critical role of cortactin for lung neutrophil infiltration and sepsis severity.

13 July 2022 in Immunology Letters
Verified
Journal Article
Closed access
NLNATHANIEL LARTEY LARTEY
NATHANIEL LARTEY LARTEY
HVHilda Vargas-Robles
Hilda Vargas-Robles
IFIdaira María Guerrero Fonseca
Idaira María Guerrero Fonseca
PNPorfirio Nava
Porfirio Nava
EKEmmanuel K. Kumatia
Emmanuel K. Kumatia
MSMichael Schnoor
Michael Schnoor

27 July 2023 in Genesis
Verified
Journal Article
Open access
NLNATHANIEL LARTEY LARTEY
NATHANIEL LARTEY LARTEY
MEMartijn van der Ent
Martijn van der Ent
RARoxann Alonzo
Roxann Alonzo
DCDi Chen
Di Chen
PKPhilip D. King
Philip D. King
Summary: Classical collagen type IV comprising of a heterotrimer of two collagen IV alpha 1 chains and one collagen IV alpha 2 chain is the principal type of collagen synthesized by endothelial cells (EC) and is a major constituent of vascular basement membranes. In mouse and man, mutations in genes that encode collagen IV alpha 1 and alpha 2 result in vascular dysfunction. In addition, mutations in genes that encode the Ephrin receptor B4 (EPHB4) and the p120 Ras GTPase‐activating protein (RASA1) that cause increased activation of the Ras mitogen‐activated protein kinase (MAPK) signaling pathway in EC result in vascular dysfunction as a consequence of impaired export of collagen IV. To understand the pathogenesis of collagen IV‐related vascular diseases and phenotypes it is necessary to identify at which times collagen IV is actively synthesized by EC. For this purpose, we used CRISPR/Cas9 targeting in mice to include immediately after the terminal Col4a1 codon a sequence that specifies a P2A peptide followed by enhanced green fluorescent protein (eGFP). Analysis of eGFP expression in Col4a1‐P2A‐eGFP mice revealed active embryonic EC synthesis of collagen IV alpha 1 through mid to late gestation followed by a sharp decline before birth. These results provide a contextual framework for understanding the basis for the varied vascular abnormalities resulting from perturbation of EC expression and export of functional collagen IV.

3 February 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MPMaxum E. Paul
Maxum E. Paul
DCDi Chen
Di Chen
KVKimberly J. Vish
Kimberly J. Vish
NLNATHANIEL LARTEY LARTEY
NATHANIEL LARTEY LARTEY
EHElizabeth Hughes
Elizabeth Hughes
TBTitus J. Boggon
Titus J. Boggon
Regulation of Ras GTPases by GTPase-activating proteins (GAPs) is essential for their normal signaling. Nine of the ten GAPs for Ras contain a C2 domain immediately proximal to their canonical GAP domain, and in RasGAP (p120GAP, p120RasGAP; RASA1 ) mutation of this domain is associated with vascular malformations in humans. Here, we show that the C2 domain of RasGAP is required for full catalytic activity toward Ras. Analyses of the RasGAP C2-GAP crystal structure, AlphaFold models, and sequence conservation reveal direct C2 domain interaction with the Ras allosteric lobe. This is achieved by an evolutionarily conserved surface centered around RasGAP residue R707, point mutation of which impairs the catalytic advantage conferred by the C2 domain in vitro. In mice, R707C mutation phenocopies the vascular and signaling defects resulting from constitutive disruption of the RASA1 gene. In SynGAP, mutation of the equivalent conserved C2 domain surface impairs catalytic activity. Our results indicate that the C2 domain is required to achieve full catalytic activity of GAPs for Ras.